BOOK BEFORE JUNE 21
& SAVE UP TO $1000

October 22-24 | Boston, MA, USA

www.macrophage-directed-therapies.com

Macrophage-directed Therapies Summit



Harness the Potential of Macrophage Therapies with CD47 Checkpoint Blockades, Engineered Macrophages and Repolarization or Depletion Strategies

Expert Speakers Include:

Hong Wan
Chief Scientific Officer
ALX Oncology

Robert Deans
Chief Technology Officer
Bluerock Therapeutics

Michael Klichinsky
Vice President, Discovery Research
Carisma Therapeutics

Leonard Reyno
Chief Medical Officer
Pionyr Immunotherapeutics

Courtney Crane
Principal Investigator
Seattle Children's Hospital

Bob Uger
Chief Scientific Officer
Trillium Therapeutics

Tel: +1 617 455 4188 **Email:** info@hansonwade.com Cell Immunotherapy

hansonwade

Welcome to the 1st Macrophage-directed Therapies Summit

Your comprehensive guide to demonstrating clinical validation of your macrophage therapeutic approach

Macrophage-directed therapies have seen a recent explosion in investment with a series of new dedicated biotechs capitalizing on their potential to rival PD1/PDL1 checkpoint inhibitors and T cell approaches in solid tumors.

At the inaugural **Macrophage-directed Therapies Summit**, we are bringing together the various approaches from **CD47 blockades** to **CAR-macrophages** to provide the whole community with one dedicated forum. Address common drug development challenges to control the fluctuating phenotype of macrophage cells and improve efficacy with combination therapies.

Leave this summit with tangible actions to **characterize the continuum of macrophage biology**, measure the homing and trafficking of cells to the tumor site and improve targeting precision to **prevent off-tumor toxicities**.

Join the trailblazers from pharma, biotech and academia who are leading the translation of macrophage-directed therapies to **learn, network** and **collaborate** to successfully achieve clinical proof of concept.

Past Attendee from the Cell & Viral Immunotherapy Series:

"One of the most progressive meetings I attend with relevant content, interesting opinions and challenges, up to the minute technology and all done in a sincerely warm and collaborative atmosphere"

Ori Biotech Ltd.

"This meeting is increasingly becoming the venue for significant breaking news in the field"

Tmunity Therapeutics

What Can You Expect?

20 World Class Speakers

19+ Case Studies

8+ Hours of Dedicated Networking

2 Intimate Discussion-based Workshops

5 Key Discussions You Can't Afford to Miss:

umcg

Characterize Macrophage Biology to Understand their Contribution to Tumor Progression

University Medical Center Groningen will review molecular imaging strategies to understand how specific macrophage subtypes contribute to tumor growth

ALX ONCOLOGY

Overcome Off-Tumor Toxicity

ALX Oncology, Trillium Therapeutics and **OSE-Immuno** will reveal strategies to specifically target tumor cells, preventing the CD47 sink effect and minimize toxicity risks like anemia

verseau

Pursue Drug Development in the Absence of Relevant *In Vivo* Models

Verseau Therapeutics and **Merck** will discuss alternative translational strategies including *ex vivo* cultures and tumor slices to review their implications for clinical translation

TG Therapeutics

Enhance Clinical Efficacy with Combination Trials

TG Therapeutics will present preclinical data supporting the rationale to use CD47 bispecific antibodies with B-cell targeted drugs to enhance clinical outcomes

MASSACHUSETTS GENERAL HOSPITAL

Opportunity for Macrophage-targeted Approaches Beyond Oncology

Massachusetts General Hospital will evaluate the role of macrophages in cardiovascular health and how their distinct subsets can pursue steady states and disease

YOUR EXPERT SPEAKERS

Hong Wan
Chief Scientific Officer
ALX Oncology

Robert Deans
Chief Technology Officer
Bluerock Therapeutics

Sergio Trombetta
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim

Dora Mitchell
Vice President, Business Development
Carisma Therapeutics

Michael Klichinsky
Vice President, Discovery Research
Carisma Therapeutics

Jennifer Guerriero
Director, Breast Immunology Laboratory
Dana-Farber Cancer Institute

Junjian Liu
Vice President, Head of Drug Discovery & Preclinical Development
Innovent Biologics

Yaron Pereg
Chief Executive Officer
Kahr Medical

Elisabeth Parker
Director of Business Development
Macrophage Pharma

Matthias Nahrendorf
Principal Investigator
Massachusetts General Hospital

Philip Brandish
Senior Principal Scientist
Merck

Yanyan Zheng
Principal Scientist, Discovery Oncology
Merck

Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics

Leonard Reyno
Chief Medical Officer
Pionyr Immunotherapeutics

Courtney Crane
Principal Investigator
Seattle Children's Hospital

Emmanuel Normant
Vice President, Preclinical Sciences
TG Therapeutics

Bob Uger
Chief Scientific Officer
Trillium Therapeutics

Carolien Schröder
Medical Oncologist
University Medical Center Groningen

Igor Feldman
Co-Founder, Vice President & Head of Computational Biology
Verseau Therapeutics

Tatiana Novobrantseva
Co-founder & Head of Research & Development
Verseau Therapeutics

FOCUS DAY TUESDAY, OCTOBER 22

Workshop A

9:00 – 12:00

Enhancing Clinical Efficacy with Macrophage Checkpoint Blockades in Combination Therapies

To increase the clinical efficacy of immuno-oncology drugs, the field is exploring different combination rationales to see which therapeutic combination will have a synergistic effect when targeting cancers. However, there are still many uncertainties with questions around dosing, safety and scheduling.

This workshop will explore macrophage biology to identify which targeted pathways have a real **science driven rationale for combination which will improve targeting, safety and overall response rate**.

Join this workshop to:

- Review TG-1801 which is a novel, bispecific antibody currently in Phase 1 that selectively targets CD47 on CD19+ B-cells, sparing red blood cells or platelets, and blocking the CD47-SIRPα macrophage checkpoint on mature B cells
- Assess Umbralisib which is an orally available PI3Kδ inhibitor that has demonstrated activity in preclinical models, primary B-NHL cells, and in patients with B-cell malignancies
- Evaluate results that set the preclinical rationale for a combination strategy of the novel CD47-CD19 antibody TG-1801 with other B-cell targeted drugs, particularly umbralisib and ublituximab, in B-NHL

Workshop Leader

Emmanuel Normant
Vice President, Preclinical Sciences
TG Therapeutics

Emmanuel Normant is currently the vice president of preclinical sciences at TG Therapeutics, a biotech focused on heme malignancies and located in New York. There, he oversees the early pipeline that includes a novel BTK inhibitor, an anti-PD-1 antibody and a bispecific antibody directed against CD19 and CD47. All three drugs are currently tested in phase 1 dose-escalation clinical trials in hematologic cancers. Dr Normant joined TG Therapeutics two years ago, bringing in 20 years expertise in cancer biology, pharmacology, immuno-oncology, cancer epigenetic and preclinical sciences.

Workshop B

13:00 – 16:00

Translational Studies using Human Tumor *Ex Vivo* Culture During Development of Myeloid-Targeting Therapies

The changing plasticity of macrophages is difficult to reproduce in animal models which lack comparable biology and immune systems.

This translational challenge limits the validation of proof of concepts and requires the field to **explore different preclinical models to analyze the safety and activity of their drug target.**

Join this workshop to:

- Understand motivation for developing *ex vivo* cultures to test macrophage-based therapies against human cancers
- Compare the advantages and disadvantages between tumor slice and tumor dissociated cultures
- Review Keytruda and macrophage-repolarizing agents' response across multiple tumor types
- Leave understanding the implications of using human *ex vivo* tumor cultures for clinical translation

Workshop Leaders

Igor Feldman
Co-Founder, Vice President & Head of Computational Biology
Verseau Therapeutics

Igor has held positions at Merck & Co., Rosetta Informatics, Jounce Therapeutics and Epizyme. He has been involved in discovery and clinical development using large omics datasets of human tumors, drug response biomarker discovery, novel target discovery in immunooncology and epigenetics.

Yanyan Zheng
Principal Scientist, Discovery Oncology
Merck

Yanyan Zheng leads the tumor intrinsic targeting and translational pathology group. Her expertise encompasses a broad range of processes in drug development, from target identification/validation, biologics discovery, to translational research.

CONFERENCE DAY ONE
WEDNESDAY, OCTOBER 23

Dora Mitchell
Vice President, Business Development
Carisma Therapeutics

9.00 Chair's Opening Remarks

Macrophage Targeting Approaches

Targeting the "Don't Eat Me Signal" to Overcome Sink Effect & Toxicity Risks

Hong Wan
Chief Scientific Officer
ALX Oncology

9.30 Targeting CD47-SIRPa Myeloid Checkpoint Pathway to Enhance Innate & Adaptive Immunity Against Cancer without Hematological Toxicity

- Discuss how ALX148, a unique CD47 blocker which is a high affinity SIRPa fusion protein linked to an inactive Fc region of human immunoglobulin, is designed to maximize the clinical benefit of antibody-based therapies and its clinical development for a broad range of tumor types
- Review preclinical studies where ALX148 bridges innate and adaptive immunity via Fc-dependent and Fc-independent mechanisms to enhance anti-tumor response in combination with targeted anti-cancer antibodies and checkpoint inhibitors with no adverse effect on CD47-expressing normal blood cells
- Understand how ALX148 is well tolerated and demonstrates antibody-like PK and complete CD47 target occupancy in cancer patients
- Discuss anti-cancer activity and translational results from Phase 1 program

Bob Uger
Chief Scientific Officer
Trillium Therapeutics

10.00 Targeting the CD47 "Do Not Eat" Signal with TTI-621 (SIRPa-IgG1 Fc)

- Evaluate TTI-621, a dual function SIRPaFc decoy receptor that inhibits the CD47 "do not eat" signal and delivers an activating signal to macrophages through Fc receptors
- Review how TTI-621 is differentiated from other CD47 blocking agents in development
- Discuss emerging clinical data

10.30 Speed Networking & Morning Refreshments

This session is fast paced aiming to provide brief introductions to as many participants at the Macrophage-Directed Therapies Summit as early on in the meeting as possible. The renowned speed networking session will be one of the most valuable hours you spend at this summit.

Junjian Liu
Vice President, Head of Drug Discovery & Preclinical Development
Innovent Biologics

11.30 Safety, Tolerability & Efficacy of CD47 Monoclonal Antibodies in Advanced Malignancies

- Discovery of IBI188, a fully human anti-CD47 therapeutic antibody
- Outline preliminary Phase 1 clinical trial results which explore recommended doses for IBI188 in combination
- Discuss future direction in CD47 blockade

Yaron Pereg
Chief Executive Officer
Kahr Medical

12.00 DSP107, a Novel Immunotherapeutic Targeting both Innate & Adaptive Immunity

- Outline Dual Signaling Protein (DSP) platform technology
- Learn about the DSP107 mechanism of action targeting both CD47 whilst simultaneously activating the immune cells via the 41BBL pathway
- Discuss CD47 targeting with a differentiated PK and safety profile

Nicolas Poirier
Chief Scientific Officer
OSE Immuno-therapeutics

12.30 Selective Anti-SIRPα Antibody: Next generation Myeloid Checkpoint Inhibitor

- Looking into OSE's approach to targeting SIRPA instead of CD47
- Review anti-SIRPa efficacy in monotherapy and combination therapies
- Discuss translational research characterizing safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in solid tumors

13.00 Lunch & Networking

Repolarizing Macrophages to Stimulate Anti-Tumor Effects

Tatiana Novobrantseva
Co-founder & Head of Research & Development
Verseau Therapeutics

14.00 Completing the Immunity Cycle by Developing Macrophage Immunotherapies

- Assess how macrophages and dendritic cells are biologically optimized to either induce or suppress an immune response
- Understand why repolarizing pro-tumorigenic macrophages has been repeatedly identified as a crucial next step for the field of immuno-oncology
- Outline how myeloid cell suppression has been fuelling the vicious cycle of the autoimmune disease
- Summarise Verseau Therapeutics' approaches to tweaking myeloid cell functionality in human disease by targeting Macrophage Checkpoint Modulators

Elisabeth Parker
Director of Business Development
Macrophage Pharma

14.30 Regulating Macrophage Polarization to Create a Tumor Suppressive Environment

- Discuss macrophage phenotypes, the tumour microenvironment and implications for immune response and prognosis
- Review Esterase Sensitive MotifTM drugs to control polarity and lock specific phenotypes
- Explore potential targets and immuno-oncology combinations

Jennifer Guerriero
Director, Breast Immunology Laboratory
Dana-Farber Cancer Institute

15.00 Targeting Macrophages for Anti-cancer Therapy

- Harness the anti-tumor potential of tumor associated macrophages for cancer immunotherapy in triple negative breast cancers
- Elucidate the diversity of myeloid cells in breast cancer
- Understand the complexity of tumor macrophages in breast cancer

Philip Brandish
Senior Principal Scientist
Merck

15.30 Therapeutic Approaches & Basic Research on Myeloid Immune Suppression in the Tumor Microenvironment

- Analyze the evidence for myeloid cell infiltrates limiting clinical responses
- Discuss the types and mechanisms of myeloid immune suppression in the TME
- Outline emerging therapeutic approaches and basic research

16.00 Afternoon Refreshments & Networking

17.00 Audience Discussion on Key Clinical Considerations for Macrophage-directed Therapies

This session is designed for you to work in groups to network and collaborate with delegates from different companies to share your insights and overcome common challenges in the field.

Topic A- Discuss the Need for Reliable & Translatable Preclinical Models

- Review and detail current preclinical models and their lack of reliable translation when replicating activity in human systems
- Discuss novel strategies for testing efficacy exploring humanised mouse models and *ex-vivo* tumor slices and tumor dissociated cultures

Topic B- Manufacturing Considerations for Characterizing & Scaling Up Macrophage Therapies

- Discuss scaling challenges with macrophages which are semi-adherent cell populations and question if this therapy has the potential to become allogeneic
- Review methods to characterize and define macrophage cell products to gain a better understanding of the cell biology
- Reflect how the antibody manufacturing space progressed to a commercial scale and how the field envision bringing that capacity to the cell engineering field

Topic C- Improve Clinical Efficacy with Combination Therapies

- Clarify the scientific rationale supporting combination therapies that would suggest better efficacy than a stand-alone macrophage monotherapy
- Address considerations around dosing, safety and scheduling of combination therapies to enhance efficacy
- Assess which combination options are relevant like chemotherapy, checkpoint inhibitors and antibodies

Sergio Trombetta
Senior Principal Scientist, Cancel Immunology & Immune Modulation
Boehringer Ingelheim

Dora Mitchell
Vice President, Business Development
Carisma Therapeutics

18.00 Chair's Closing Remarks

"This meeting gave us the chance to understand a growing and important therapeutic field. It allowed us to make decisions that were a win-win for our organization and the patient"

Past Attendee from the Cell & Viral Immunotherapy Series, Roche Diagnostics Group

CONFERENCE DAY TWO
THURSDAY, OCTOBER 24

9.00 Chair's Opening Remarks

Characterizing Success in Macrophage-directed Therapy

Leonard Reyno
Chief Medical Officer
Pionyr Immunotherapeutics

Courtney Crane
Principal Investigator
Seattle Children's Hospital

9.30 Panel Discussion: Defining Metrics of Success with Macrophage-directed Therapeutics

Key questions to address:

- What does success look like when manipulating macrophage phenotypes?
- Is success defined through restructuring the tumor microenvironment or activating t cell infiltration to the tumor site?
- What will be the most relevant strategy clinically addressing macrophages?
- Define the most important parameters around this modality that will reflect translational viability in humans

Characterize Macrophage Cell Types with Novel Biomarkers to Understand their Contribution to Tumor Progression

Carolien Schröder
Medical Oncologist
University Medical Center Groningen

10.30 Exploiting Macrophages as a Target for Therapy in Breast Cancer (BC)

- Analyze the macrophage profile in BC subpopulations
- Review translational approaches to incorporate macrophage targeting in BC treatment
- Outline molecular imaging strategies to guide these approaches

11.00 Morning Refreshments & Networking

Genetically Engineered Macrophages to Target Solid Tumor Sites

Courtney Crane
Principal Investigator
Seattle Children's Hospital

12.00 Testing Genetically Engineered Macrophages to Transform the Solid Tumor Microenvironment

- Outline pre-clinical genetically modified macrophage data and path to clinic
- Discuss additional payloads for future and combination approaches
- Considerations for mechanistic insight in clinical trials to inform future design

Michael Klichinsky
Vice President, Discovery Research
Carisma Therapeutics

12.30 CAR Macrophages: Tailor-Made for Solid Tumor Immunotherapy

- Address current challenges in solid tumor cellular therapy
- Overview of the Carisma CAR Macrophage platform
- Review the promise of CAR Macrophages in solid tumors

Depleting Immunosuppressive Macrophage Cells to Enhance Antitumor Immunity

Leonard Reyno
Chief Medical Officer
Pionyr Immunotherapeutics

13.00 Depleting Tumor-associated Macrophages to Create an Immune Stimulatory Environment

- Identify which population of immunosuppressive cells should be targeted to deplete
- Outline the safety and toxicity potential of this type of strategy
- Review the clinical translation opportunity of this therapy in combination

13.30 Lunch & Networking

Future Drug Development Opportunities for Macrophage-directed Therapies

Robert Deans
Chief Technology Officer
Bluerock Therapeutics

14.30 Engineering Next Generation Macrophage from iPSC

- Enable allogeneic practice by gene editing the immune locus
- Control macrophage polarity using synthetic biology and logic circuits
- Understand how iPSC manufacturing transforms treatment paradigms from a transplant model to biologics

Matthias Nahrendorf
Principal Investigator
Massachusetts General Hospital

15.00 Macrophages in Cardiovascular Health

- Discuss the biology of monocytes and macrophages that reside and accumulate in atherosclerotic lesions but also in the healthy and injured heart and brain
- Outline how cells and their subsets pursue distinct functions in steady state and disease, and their tenure may range between hours to months; some subsets are highly inflammatory, while others support tissue repair
- Review current concepts of cell supply by the hematopoietic system, lineage relationships and systems' cross talk
- Evaluate imaging tools for studying monocytes, macrophages and their progenitors

15.30 Chair's Closing Remarks

"This meeting gave a fresh and extensive update on what's going on in the field and the opportunity to establish new networks and consolidate established ones"

Past Attendee from the Cell & Viral Immunotherapy Series, MolMed S.p.A

PARTNERSHIP OPPORTUNITIES

Are you looking to work with pharma, biotech and academic institutes that are developing Macrophage-directed therapies?

Macrophage-directed Therapies Summit is the only comprehensive meeting dedicated to overcoming the challenges faced by the macrophage community in their efforts to identify proof of concept in this field.

Following on from the excitement in the cellular immune revolution, macrophages are now being considered as the next therapeutic area where immunotherapy can make a significant difference in conquering solid tumors due to their inherent ability to accumulate in the tumor microenvironment.

With the existing momentum to move macrophage-directed therapies into the clinic, drug developers are actively seeking external expertise across **biomarker identification, safety and efficacy testing, *in-vivo* imaging, commercially viable manufacture** and **experienced clinical research.**

Can you support the development of the next generation of immunotherapies?

Showcase Expertise and Build Credibility
Take this opportunity to demonstrate your preclinical and clinical expertise to an exclusive community of decision makers in search of support.

Build Relationships with Senior Level Decision Makers
Network with all of the leading members of the macrophage community in one room over three days. Use this platform to interact and hear first-hand the challenges that industry leaders face.

Drive Your Brand to Forefront of Mind
As pharma, biotech and academia seek out-of-house expertise, are you front of mind? Take this chance to benefit from increased exposure, differentiate your company from competitors and ensure you identify as a leader of the macrophage space.

Partnering with the **Macrophage-directed Therapies Summit** will ensure you capitalize on the market early, cement your position as an industry leader and support the rate of discovery and clinical translation of targeted, safe and effective macrophage-directed therapies.

Audience Seniority*

- **C-Level: 12%**
- **Director Level and Above : 51%**
- **Head of: 24%**
- **Scientist: 13%**

*Based on previous Hanson Wade events' statistics

Attendance by Industry Type*



- **Drug Developers**
- **Academics**
- **Solution and Service Providers**
- **Investors and Analysts**

"While cell therapies are the new face of medicine with more questions than answers, the ability to interact with these thought leaders is a unique opportunity to gain relevant insight and answers"

Past Attendee from the Cell & Viral Immunotherapy Series, CryoPort

To become a Partner contact:

Luke O'Neill
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.macrophage-directed-therapies/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

Gain a comprehensive understanding of the current landscape and future development opportunities with combination therapies and indications beyond oncology

Learn from the key thought leaders in the field to improve your understanding of macrophage biology and how the various subtypes contribute to tumor progression

Network with pioneering leaders of the macrophage community and take this opportunity to create collaborative partnerships for future clinical prospects

Team Discounts*

10% discount- 3 Delegates
15% discount- 4 Delegates
20% discount- 5 or More Delegates
***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.**
Contact: register@hansonwade.com

SECURE YOUR PLACE

Drug Developer Pricing*	Register & Pay before Friday June 21, 2019	Standard Prices
Gold: Conference & 2 workshops	$3097 **(save $1000)**	$3897 **(save $200)**
Silver: Conference & 1 workshop	$2598 **(save $900)**	$3398 **(save $100)**
Bronze: Conference only	$2099 **(save $800)**	$2899
Workshops: Individual	$599	

Academic Pricing	Register & Pay before Friday June 21, 2019	Standard Prices
Gold: Conference & 2 workshops	$1697 **(save $1000)**	$2497 **(save $200)**
Silver: Conference & 1 workshop	$1298 **(save $900)**	$2098 **(save $100)**
Bronze: Conference only	$899 **(save $800)**	$1699
Workshops: Individual	$499	

Standard Pricing	Register & Pay before Friday June 21, 2019	Standard Prices
Gold: Conference & 2 workshops	$3697 **(save $1000)**	$4497 **(save $200)**
Silver: Conference & 1 workshop	$3098 **(save $900)**	$3898 **(save $100)**
Bronze: Conference only	$2499 **(save $800)**	$3299
Workshops: Individual	$699	

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.
*Must be from a biotech or pharma company that is currently and publicly developing a macrophage-directed therapy to be eligible for this price.

VENUE

Aloft Boston Seaport District
401-403 D Street,
Boston, Massachusetts, 02210, USA

www.marriott.co.uk/hotels/travel/bosal-aloft-boston-seaport-district/